hotspot -WSS

hotspot

author：fashion 2025-09-27 23:31:33 - browse：15174

Adam's take main illustration — Molly Ferguson/STAT

The approval Friday of Bluebird Bio’s gene therapy for sickle cell disease should have been a momentum-swinging achievement for the long-struggling biotech. Instead, the company mispriced its new drug and fumbled a pivotal financial lifeline.

The consequences of these strategic blunders — arguably, self-inflicted — could imperil Bluebird’s independence, perhaps even its survival.

Bluebird priced Lyfgenia at $3.1 million, while Vertex Pharmaceutical set the cost of Casgevy, its competing sickle cell treatment also approved on Friday, at $2.2 million. Not only is Lyfgenia significantly more expensive, but its prescribing label carries a “black box” safety warning, which requires patients undergo regular blood monitoring for cancer risk. Casgevy has no similar monitoring requirement.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Walensky prepares to leave CDC — and Congress — behind
Next article： Why CTE doesn’t keep Americans from enjoying the Super Bowl

knowledge

WSS

Global cancer cases to surge 77% by 2050, WHO report says

House panel to mark up pandemic

Top private equity targets in 2023: cardiology, clinical trials, lasers

Another man arrested in connection with shooting at Kansas nightclub

What could happen if Russia blows up the Zaporizhzhia Nuclear Power Plant?

Gritstone Bio's cancer vaccine test, and more on Novartis' deal

entertainment

hotspot

entertainment

Moonlake's readout produced a cash windfall. Risks remain

Cano Health’s bankruptcy is a warning for Medicare Advantage

Jerome Adams on the need for new antivirals for Covid

The Biogen Aduhelm mess could happen again

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Readout LOUD: Venture capital, Gilead, and more M&A

In age of alternative facts, a scholarly course on calling out crap

What could happen if Russia blows up the Zaporizhzhia Nuclear Power Plant?

Jerome Adams on the need for new antivirals for Covid

Masked men burn a market in a Mexican city plagued by gang violence, killing 9 people

explore

Bernie brings in new pharma CEOs to talk drug prices

Tennessee woman gets emergency hysterectomy after doctors deny early abortion care

The Biogen Aduhelm mess could happen again

Drinking water from half of US faucets contains PFAS: Study

Vyjuvek, a gene therapy for skin wounds, restored vision in one boy

With fresh data, a dynamic duo powers Eli Lilly to new heights

entertainment

knowledge

explore

knowledge